Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial
CNS Drugs · 2025-11 · 39 (11) · 1157-1172
DOI: 10.1007/s40263-025-01209-0 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift CNS Drugs, online erschienen am 13.08.2025. Verfasst von Robert L Findling und 9 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Richmond, VA, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Viloxazine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Supernus Pharmaceuticals.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Viloxazine ER (extended-release capsules; Qelbree®) is a nonstimulant medication that has been approved by the United States Food and Drug Administration (FDA) for treatment of pediatric and adult attention-deficit/hyperactivity disorder (ADHD). This phase 3, open-label extension (OLE) trial evaluated the long-term safety and efficacy of viloxazine ER in children and adolescents with ADHD. METHODS: Participants completing the phase 2 or one of the four phase 3 double-blind, placebo-controlled clinical trials were eligible for the OLE trial. Upon entering the OLE, double-blind treatment was discontinued and participants were administered viloxazine ER 100 mg/day (children, aged 6-11 years) or 200 mg/day, (adolescents, aged 12-18 years), with dosage titration as needed over a 12-week dose-optimization period (up to 400 mg/day [children] or 600 mg/day [adolescents]). Participants then entered a maintenance period that continued through US FDA-approval (up to 72 months). Safety (primary objective) was assessed relative to OLE baseline using adverse event (AE), clinical laboratory tests, vital sign, ECG, and Columbia Suicide Severity-Rating Scale (C-SSRS) monitoring. Efficacy was assessed relative to double-blind baseline using the ADHD Rating Scale (ADHD-RS-IV/5) and the Clinical Global Impression-Improvement (CGI-I) scale. Study visits for these assessments occurred every ~ 3 months throughout maintenance treatment. RESULTS: Participants (N = 1100) included 646 children and 454 adolescents (66.5% male/33.5% female). Median (range) exposure to viloxazine ER in the OLE was 260 (1-1896) days, and the median modal (most frequently used) viloxazine ER doses were 300 mg/day for children and 400 mg/day for adolescents. AEs included (≥ 5% incidence) nasopharyngitis (9.7%), somnolence (9.5%), headache (8.9%), decreased appetite (6.0%), and fatigue (5.7%). AEs were mostly mild or moderate in severity (3.9% reported any severe AE); AEs led to discontinuation in 8.2% of participants. The mean ± SD changes from double-blind baseline in ADHD-RS IV/5 total score were -24.3 ± 12.0 at Month 3, -26.1 ± 11.5 at Month 12, and -22.4 ± 13.6 at participants' last OLE study visit. CONCLUSIONS: The results of this large-scale safety trial support the long-term use of viloxazine ER as a generally well-tolerated and effective treatment option for pediatric ADHD. No new safety concerns emerged, and efficacy results suggest the potential for continued improvement over that seen during double-blind treatment. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02736656.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Virginia Commonwealth University, Richmond, VA, USA.
- Houston Clinical Trials, Bellaire, TX, USA.
- The Medical Research Network LLC, New York, NY, USA.
- Penn State College of Medicine, Hershey, PA, USA.
- Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
- Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA. jrubin@supernus.com.
Förderung
- Supernus Pharmaceuticals
Zitieren
APA
Findling, R. L., Katic, A., Liebowitz, M., Waxmonsky, J., Fry, N., Qin, P., Yarullina, I., Maldonado-Cruz, Z., Lieberman, V. R., & Rubin, J. (2025). Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial. CNS Drugs, 39(11), 1157-1172. https://doi.org/10.1007/s40263-025-01209-0
Vancouver
Findling RL, Katic A, Liebowitz M, Waxmonsky J, Fry N, Qin P, et al. Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial. CNS Drugs. 2025;39(11):1157-1172. doi:10.1007/s40263-025-01209-0
BibTeX
@article{Findling2025,
author = {Findling, Robert L and Katic, Alain and Liebowitz, Michael and Waxmonsky, James and Fry, Nicholas and Qin, Peibing and Yarullina, Ilmiya and Maldonado-Cruz, Zulane and Lieberman, V Rose and Rubin, Jonathan},
title = {Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial},
journal = {CNS Drugs},
year = {2025},
volume = {39},
number = {11},
pages = {1157--1172},
doi = {10.1007/s40263-025-01209-0}
}
EUVIMED